Cantor Fitzgerald Expects Higher Earnings for Septerna

Septerna, Inc. (NASDAQ:SEPN) – Cantor Fitzgerald increased their FY2025 earnings per share estimates for Septerna in a report released on Wednesday, February 19th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings of ($2.40) per share for the year, up from their prior forecast of ($2.58). Cantor Fitzgerald currently has a “Overweight” rating and a $50.00 target price on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share.

A number of other research analysts have also commented on SEPN. Wells Fargo & Company lowered Septerna from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $43.00 to $14.00 in a report on Tuesday. JPMorgan Chase & Co. initiated coverage on Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price target for the company. Finally, TD Cowen initiated coverage on Septerna in a research report on Tuesday, November 19th. They set a “buy” rating on the stock.

Septerna Price Performance

Shares of SEPN stock opened at $5.80 on Friday. Septerna has a 12 month low of $4.17 and a 12 month high of $28.99. The stock’s 50 day simple moving average is $17.78.

Insider Activity

In other news, CFO Gil M. Labrucherie acquired 10,500 shares of the stock in a transaction dated Wednesday, February 19th. The shares were acquired at an average cost of $5.51 per share, for a total transaction of $57,855.00. Following the completion of the transaction, the chief financial officer now owns 10,500 shares in the company, valued at approximately $57,855. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Institutional Trading of Septerna

A number of large investors have recently bought and sold shares of the stock. Woodline Partners LP bought a new stake in Septerna in the fourth quarter valued at $6,870,000. Zimmer Partners LP bought a new stake in Septerna in the fourth quarter valued at $229,000. Soleus Capital Management L.P. bought a new stake in Septerna in the fourth quarter valued at $15,467,000. Nuveen Asset Management LLC bought a new stake in Septerna in the fourth quarter valued at $549,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Septerna in the fourth quarter valued at $278,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.